ADCY1

ADCY1 is a Ca2+/calmodulin-stimulated adenylyl cyclase that converts ATP to cAMP and serves as a context-dependent hub for localized cAMP signaling in sensory, neuronal, epithelial, and cardiac cells (PMID:24482543, PMID:29331508). Its carboxyl-terminal catalytic domain is required both for enzymatic efficiency and calmodulin stimulation and for targeting the protein to actin-based microvilli and cochlear hair cell stereocilia; a nonsense mutation that truncates 82 C-terminal residues abolishes catalytic activity, and loss of function disrupts hair cell mechanotransduction (PMID:24482543). ADCY1 generates compartmentalized cAMP when recruited to plasma membrane signalosomes upon GPCR stimulation, where it co-assembles with EPAC1 alongside CFTR and TMEM16A to couple Ca2+- and cAMP-dependent chloride channel signaling (PMID:29331508), and it is similarly activated downstream of NAADP-driven lysosomal Ca2+ release to mediate α-adrenergic chronotropic and inotropic responses in atrial myocytes [PMID:bio_10.1101_2024.11.25.625232]. In neurons, Adcy1 mRNA translation is repressed by FMRP; loss of FMRP elevates ADCY1 protein, driving aberrant ERK1/2- and PI3K-mediated signaling, excessive protein synthesis, dendritic spine abnormalities, and autism-related behaviors that are corrected by reducing ADCY1 (PMID:28218269), and ADCY1-mediated cAMP also governs neural maturation in human forebrain organoids (PMID:40471331). ADCY1 transcription is enhanced by direct promoter binding of CUX2, through which it mediates tumor suppression in glioma (PMID:36242624), and is positively regulated by upstream INHBB signaling to drive cAMP-mediated decidualization in endometrial stromal cells (PMID:36913138).

1. 2000 Medium

   Established Adcy1 as a genetically defined locus by identifying the causative loss-of-function lesion behind the barrelless phenotype, linking the gene to neural patterning.

   Evidence Northern blot, RT-PCR, and LTR phylogenetic analysis of an ETn retrotransposon insertion in mouse Adcy1

   PMID:10656922

   Open questions at the time

   • Does not define the biochemical activity of the lost protein
   • Mechanism connecting transcript loss to neural patterning not resolved
2. 2014 High

   Defined ADCY1 as a Ca2+/calmodulin-stimulated adenylyl cyclase whose C-terminal catalytic domain governs both activity and stereocilia localization, establishing its essential role in hair cell mechanotransduction.

   Evidence Whole-exome sequencing of a deafness mutation, COS-7 truncation/localization assays, zebrafish morphant FM1-43 and startle assays, mouse immunolocalization

   PMID:24482543

   Open questions at the time

   • How the C-terminus targets actin-based microvilli mechanistically is unresolved
   • No structural model of the catalytic domain–calmodulin interaction
3. 2017 High

   Showed ADCY1 is a translationally repressed FMRP target whose overproduction drives the aberrant ERK1/2 and PI3K signaling and behavioral deficits of fragile X, identifying ADCY1 as a therapeutic node.

   Evidence Fmr1/Adcy1 double-KO epistasis, polyribosome translation assays, signaling immunoblots, spine morphology, behavior, and NB001 pharmacology in mice

   PMID:28218269

   Open questions at the time

   • Direct biochemical link from cAMP output to ERK1/2 and PI3K activation not delineated
   • Whether effects are cell-autonomous to specific neuron types unaddressed
4. 2018 Medium

   Demonstrated that ADCY1 is recruited into GPCR-organized plasma membrane signalosomes to produce compartmentalized cAMP, providing a mechanism for Ca2+-to-cAMP crosstalk at chloride channels.

   Evidence siRNA knockdown, live-cell imaging, patch-clamp electrophysiology, fractionation, and cAMP biosensors in airway epithelial cells

   PMID:29331508

   Open questions at the time

   • Scaffold proteins recruiting ADCY1 to the GPCR domain not identified
   • Single cell type; generality across epithelia untested
5. 2022 Medium

   Placed ADCY1 downstream of the CUX2 transcription factor, identifying transcriptional control of ADCY1 as a route to tumor suppression in glioma.

   Evidence Dual-luciferase reporter and ChIP for promoter binding, gain/loss-of-function rescue, proliferation/migration assays, and xenografts

   PMID:36242624

   Open questions at the time

   • cAMP-dependence of the tumor-suppressive effect not directly tested
   • Downstream effectors mediating growth suppression unidentified
6. 2023 Medium

   Identified INHBB as an upstream positive regulator of ADCY1 driving cAMP-mediated decidualization, extending ADCY1 signaling into reproductive biology.

   Evidence siRNA knockdown, RNA-seq, forskolin rescue, and correlation analysis in human endometrial stromal cells

   PMID:36913138

   Open questions at the time

   • Mechanism by which INHBB regulates ADCY1 (transcriptional vs other) not defined
   • Direct vs indirect regulation not distinguished
7. 2024 Medium

   Linked NAADP-driven lysosomal Ca2+ release to ADCY1/AC8 activation, defining a chamber-specific mechanism coupling α-adrenergic stimulation to cAMP and atrial contractility.

   Evidence Adcy1/Adcy8 double-KO mice, NAADP pathway inhibitors, cAMP FRET biosensor, Ca2+ transient imaging, and contractility in isolated myocytes (preprint)

   PMID:bio_10.1101_2024.11.25.625232

   Open questions at the time

   • Relative contributions of ADCY1 vs AC8 not separated
   • Preprint not yet peer-reviewed
   • Spatial relationship between lysosomal Ca2+ and ADCY1 not visualized
8. 2024 Low

   Associated elevated ADCY1 with cisplatin resistance in lung cancer cells, suggesting ADCY1 modulates apoptotic and cell-cycle responses to chemotherapy.

   Evidence siRNA knockdown/overexpression, MTT/CCK-8, flow cytometry for apoptosis and cell cycle, and RNA-seq in A549/H1299 cells

   PMID:39338283

   Open questions at the time

   • No direct biochemical mechanism linking cAMP to apoptosis established
   • Single lab, no in vivo validation
9. 2025 Medium

   Established ADCY1-mediated cAMP as the mechanistic hub for montelukast-induced neural maturation defects in a human model, reinforcing ADCY1's role in neurodevelopment.

   Evidence Human forebrain organoids with ST034307 inhibition, ADCY1 overexpression rescue, cAMP measurement, neuroactivity recording, and transcriptomics

   PMID:40471331

   Open questions at the time

   • How montelukast downregulates ADCY1 transcription not defined
   • Downstream cAMP effectors driving maturation unidentified

• How ADCY1's catalytic activity, calmodulin/Ca2+ sensing, and subcellular targeting are integrated to produce the distinct compartmentalized cAMP outputs across hair cells, neurons, epithelia, and myocytes remains unresolved.
• No unified structural or scaffolding model across cell types
• Effector coupling (EPAC1, PKA, channels) characterized only piecemeal
• Determinants of tissue-specific signalosome assembly unknown